Pivoted to nuzefatide after regulators rejected zelenectide's approval path; thesis now rides on Phase 2 PDAC efficacy data in 2027

Bicycle Therapeutics is a clinical-stage company developing a targeted cancer drug for pancreatic cancer that is not yet approved.

After FDA, EMA, and MHRA rejected the Duravelo-2 trial design as an approval path for zelenectide in bladder cancer, Bicycle cut its workforce 30% and recentered on nuzefatide, an EphA2-targeting bicyclic peptide-drug conjugate in Phase 2 for recurrent pancreatic cancer, one of oncology's hardest-to-treat diseases. The thesis resolves on whether nuzefatide's 2027 Phase 2 efficacy readout shows meaningful tumor response in PDAC, supported by preclinical sensitivity in 10 of 14 PDX models and EphA2 target validation in human imaging. The central risk is that single-arm Phase 2 data in PDAC may not constitute a registrational path, and zelenectide retains no confirmed route to approval despite its randomized Phase 2 activity.